Finalists Announced for 2018 Diabetes Innovation Challenge
24 avr. 2018 08h10 HE
|
T1D Exchange
BOSTON, April 24, 2018 (GLOBE NEWSWIRE) -- T1D Exchange, a nonprofit patient-centered research organization dedicated to accelerating novel treatments to improve the lives of people with type 1...
INVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKS
13 déc. 2017 13h13 HE
|
Azzad Funds
Falls Church, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SOURCE - AZZAD ASSET MANAGEMENT Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information...
CrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research Programs
21 nov. 2017 08h00 HE
|
Crown Bioscience
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development...
PharmaCyte Going Head to Head with Eli Lilly's Pancreatic Cancer Drug in New Clinical Trial
24 janv. 2017 09h10 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - January 24, 2017) - Ten years ago the National Cancer Institute (NCI) recognized the rise in pancreatic cancer deaths and called for the development of better treatments....
PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
15 oct. 2015 09h25 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - October 15, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) advanced pancreatic cancer treatment of Cell-in-a-Box® capsules + low-doses of ifosfamide has outperformed Eli...
Celgene May Also Want to Take Notice of PharmaCyte Biotech
24 juil. 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 24, 2015) - A recent deal between Celgene and Juno Therapeutics is just a microcosm of the mindset that may ultimately drive a similar deal between it -- or a...
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board
21 juil. 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 21, 2015) - In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is,...
PharmaCyte Biotech's Cell-in-a-Box Technology Makes Good Cancer Drugs Better
13 juil. 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 13, 2015) - While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
18 mars 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
14 oct. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...